Tenderwize
Wróć do wyszukiwania

Open-house rebate contracts for valproic acid (non-retarded form)

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Apr 03, 2028 · 584 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Valproinsäure in nicht retardierter Darreichungsform, ATC N03AG01

62/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

62 / 100

Złożoność

58 / 100

Czynniki ryzyka

Paper documents sent to the wrong channel or not received as original duplicate copies by the stated deadline may be in...

Only pharmaceutical companies are eligible, and a signed declaration of reliability is mandatory.

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until May 2028
  • Open-house rebate agreements for the medicinal product valproic acid in non-retarded dosage form, ATC N03AG01.
  • Supply contract for pharmaceutical products.
Pokaż pełne podsumowanie

This is an open-house pharmaceutical supply arrangement by AOK Bayern for valproic acid in non-retarded form (ATC N03AG01), not a competitive award procedure in the usual sense. The buyer intends to conclude identical, non-exclusive contracts with all interested pharmaceutical companies that meet the stated suitability requirement. The contract period runs from 2026-06-01 to 2028-05-31, with contract conclusion possible until 2028-04-03. Submission is possible electronically via DTVP with a qualified electronic signature or in paper form in duplicate originals; German language is required, and non-German documents must be submitted with German translation. No contract value is provided.

Ryzyka

Paper documents sent to the wrong channel or not received as original duplicate copies by the stated deadline may be in...

Only pharmaceutical companies are eligible, and a signed declaration of reliability is mandatory.

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • A signed declaration of reliability must be submitted.
  • The signed contract and the completed annex 'Determination of the medicinal products covered by the contract' must be submitted.

Zamawiający

Lokalizacja

München, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE811695320

Działalność

Health

Części (1)

LOT-0001

Open-house rebate contracts for valproic acid (non-retarded form)

Single lot from structured data. Scope: open-house rebate agreements for pharmaceutical products containing valproic acid in non-retarded dosage form, ATC N03AG01. The arrangement is non-exclusive and identical for all qualifying pharmaceutical companies. Place of performance is Germany, Bavaria (DE212).

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

DE212, Germany

Czas trwania

May 2026 - May 2028

Kategoria

Pharmaceutical products

Termin

Deadline Apr 03, 2028

Szczegóły zamówienia

Data publikacji
14 Apr 2026
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
255761-2026

Dokumenty (2)

Dokument zamówienia 1Portal składania ofert 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30